Welcome to our dedicated page for Optinose news (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on Optinose stock.
OptiNose Inc. reports news centered on XHANCE, its FDA-approved drug-device combination product for adults with chronic rhinosinusitis with or without nasal polyps. XHANCE uses the Exhalation Delivery System to deliver fluticasone propionate to high and deep regions of the nasal cavity where sinuses ventilate and drain.
Company updates commonly cover XHANCE net revenue, prescription trends, financial results, commercial execution with ear, nose and throat and allergy specialists, and operating highlights. OptiNose news also includes corporate presentations, material agreements, shareholder voting matters, and capital-structure actions related to its public listing.
Optinose (NASDAQ:OPTN) announced that CEO Peter Miller will deliver a company overview and business update at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020, at 10:20 a.m. ET. Investors can access a live webcast of the presentation via the Investors page on the Optinose website. A replay will be available for 30 days post-event. Optinose focuses on patients treated by ENT and allergy specialists.
Optinose (NASDAQ:OPTN) reported first quarter 2020 financial results, highlighting a net revenue of $7.1 million from XHANCE, a 149% increase in prescriptions compared to Q1 2019. The COVID-19 pandemic impacted growth but prescriptions rose by 8% in late April. The company withdrew its 2020 revenue guidance due to uncertainty caused by the pandemic but plans to reduce operating expenses by $17 million. As of March 31, 2020, cash and cash equivalents were $148.5 million, with a net loss of $28.9 million, or $0.63 per share.
Summary not available.